# Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT04752696** · PHASE2 · COMPLETED · sponsor: **Cardiff Oncology** · enrollment: 41 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Onvansertib
- **DRUG:** Nanoliposomal irinotecan
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT04752696
- **Lead sponsor:** Cardiff Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-25
- **Primary completion:** 2024-12-24
- **Final completion:** 2024-12-24
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04752696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04752696, "Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04752696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*